We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Detects Silent Cardiac Disease

By LabMedica International staff writers
Posted on 26 Aug 2015
Print article
Image: Schematic representation of the protein biomarkers used in the Cardiac Protein Unstable Lesion Signature (PLUs) test (Photo courtesy of GD Biosciences).
Image: Schematic representation of the protein biomarkers used in the Cardiac Protein Unstable Lesion Signature (PLUs) test (Photo courtesy of GD Biosciences).
A blood test has been developed that detects silent cardiac disease and assesses a person’s risk of suffering from a future cardiac event.

The test analyzes clinically-validated, multiplexed serum protein assays to measure proteins related to inflammation, apoptosis, thrombosis, vascular remodeling, and other processes underlying Unstable Cardiac Lesion formation and chronic heart disease (CHD) development.

The Cardiac Protein Unstable Lesion Signature test (PLUs; Irvine, CA, USA) detects evidence of heart disease in asymptomatic individuals and predicts their risk of a future coronary event with unparalleled accuracy. The simple blood test analyzes the proteins secreted from active lesions in the coronary arteries. Measured with other factors including age, race and gender, as well as in conjunction with current testing practices, the heart disease assessment test is able to identify underlying silent cardiac disease activity and predict the likelihood of a future cardiac event within a five year window.

The Cardiac PLUs Test was developed by Global Discovery Biosciences (GD Biosciences; Irvine, CA, USA). Current risk stratification tools that rely on traditional risk factors fail to accurately identify those who are at risk of a heart attack. In fact, over 50% of individuals presenting with a severe cardiac event have at most one risk factor or normal cholesterol levels. The test has been validated in a multiethnic population and outcome data demonstrates clinical utility in identifying at-risk patient.

Douglas S. Harrington, MD, CEO of GD Biosciences, said, “This test is a monumental step forward in combatting the world’s deadliest killer heart disease. The ability to identify underlying silent cardiac disease and predict the likelihood of a cardiac event before it happens is crucial in the health of a patient, especially those who are not showing any symptoms. We know the test saves lives, it has done so numerous times already, now it’s just making people aware of their options and expanding accessibility.” The Cardiac PLUs Test was recently presented at the 20th World Congress on Heart Disease held July 25–27, 2015, in Vancouver (BC, Canada).

Related Links:

Cardiac PLUs Test 
GD Biosciences


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.